Saturday 17 October 2026
Export SEPN’s income statement to Excel — free account
Septerna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22,375.6%, EPS grew 48.2% and free cash flow fell 9.01%, each against the same quarter a year earlier.
36.05
1.40
−3.74%
Follow SEPN
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
Piotroski F-Score |
5 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 |
Altman Z-Score |
3.41 | 3.68 | — |
P/S ratio |
26.85 | 210.70 | 58.37 |
Altman Z″-Score (non-manufacturers) |
3.75 | 14.99 | 4.01 |
P/FCF ratio |
10.10 | 0.00 | 0.00 |
Beneish M-Score |
32.85 | 2.67 | — |
P/Operating CF |
(82.33) | (10.81) | (3.11) |
P/B ratio |
3.23 | 0.54 | 0.00 |
Price to Tangible BV |
3.23 | 0.54 | 0.00 |
EV/Sales |
18.34 | (115.74) | (87.31) |
EV/EBITDA |
0.00 | 1.57 | 1.17 |
EV/Operating CF |
7.65 | 1.84 | 1.41 |
EV/FCF |
6.90 | 2.65 | 2.21 |
Quick Ratio |
4.62 | 27.32 | 16.09 |
Current Ratio |
4.73 | 27.77 | 16.30 |
Net Debt/EBITDA |
5.86 | 4.42 | (30.27) |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.09 | 0.00 | 0.00 |
Operating CF/Net income |
(2.25) | 0.94 | (68.29) |
Capex/Depreciation |
7.47 | 14.65 | 26.09 |
| (12.19%) | (37.62%) | 0.00% | |
| (9.29%) | (24.45%) | 0.00% | |
ROIC |
0.00% | (73.08%) | 0.00% |
Return on Tangible Assets |
(14.88%) | (20.57%) | 0.51% |
Average Days of Receivables |
82.26 | 58.06 | 55,054.57 |
Research and Development Expense of Revenue |
212.37% | 6,077.86% | 23,827.15% |
Selling, General and Administrative Expense of Revenue |
63.47% | 1,540.56% | 6,438.41% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
18.45% | 293.21% | 1,072.85% |
Graham Net Nets |
0.16 | 1.41 | (2.45) |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(3.98%) | (97.90%) | (127.24%) |
Free Cash Flow Yield |
9.90% | (20.73%) | (67.71%) |
Revenue per Share |
1.04 | 0.11 | 0.08 |
Operating CF per Share |
2.49 | (6.82) | (20.07) |
Capex per Share |
0.27 | 2.07 | 11.47 |
Free Cash Flow per Share |
2.76 | (4.75) | (8.61) |
Cash per Share |
8.84 | 35.48 | 45.87 |
Shareholders Equity per Share |
8.63 | 42.47 | (19.89) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
8.63 | 42.47 | (19.89) |
Free Cash Flow |
122.17 | (46.95) | (16.60) |
Working Capital |
324.03 | 343.98 | 105.76 |
Capital Expenditures |
11.98 | 20.52 | 22.12 |
Net Current Asset Value |
196.70 | 320.32 | (56.56) |
EV/EBIT |
0.00 | 1.54 | 1.15 |
Capex to Sales |
(0.26) | (19.09) | (146.50) |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.36 | 0.28 | 0.18 |
Cash ROIC |
15.80% | (6.09%) | (33.13%) |
Accounts Receivable Turnover |
8.73 | 0.09 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Receivables |
5.26 | 11.47 | — |
Average Payables |
6.74 | 2.92 | — |
Average Assets |
526.37 | 293.71 | — |
Average Common Equity |
400.99 | 190.84 | — |
Columns are period end dates